Wie hoch ist der Preis für Aequus Pharmaceuticals Inc. (AQS)

Preis für Aequus Pharmaceuticals Inc. (AQS) ist $0.00359455

Wie hoch ist die Marktkapitalisierung für Aequus Pharmaceuticals Inc. (AQS)

Marktkapitalisierung für Aequus Pharmaceuticals Inc. (AQS) ist $476.76K

Aequus Pharmaceuticals Inc. (AQS) Aktiensplits

Aequus Pharmaceuticals Inc. is a specialized Canadian pharmaceutical company dedicated to advancing and commercializing therapeutic solutions. Its core operations span critical areas such as neurology, ophthalmology, and transplantation. The company currently markets a range of products, including Vistitan, an ophthalmic treatment designed to alleviate elevated intraocular pressure in individuals suffering from open-angle glaucoma or ocular hypertension. Another key offering is Tacrolimus IR, an immunosuppressant vital for both preventing and treating acute rejection in organ transplant recipients. Aequus also provides its Evolve line of dry eye products, which target various symptoms associated with dry eye disease and blepharitis, such as discomfort, stinging, burning, and dryness, alongside a preservative-free ophthalmic option. In its development pipeline, Aequus is progressing several innovative candidates. These include Topiramate XR and Oxcarbazepine XR, extended-release oral tablets aimed at epilepsy treatment; AQS1303, a transdermal formulation of pyridoxine/doxylamine developed to combat nausea and vomiting during pregnancy; and AQS1304, a cannabinoid-based therapeutic under investigation for neurological disorders. To support its market reach and innovation, Aequus has forged strategic alliances. These include an agreement with Sandoz Canada, Inc. for the promotion of Vistitan; a partnership with Supernus Pharmaceuticals, Inc. for the marketing of its extended-release anti-epileptic drugs; and a collaboration with Medicom Healthcare Ltd. centered on preservative-free ophthalmic treatments. Established in 2013, Aequus Pharmaceuticals Inc. maintains its corporate headquarters in Vancouver, Canada.

Jahr	Aktien-Split	Multiplikator	Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.

Jahr

Aktien-Split

Multiplikator

Kumulierter Multiplikator

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	Anzahl der Aktiensplits	Kumulierter Multiplikator	Land
MERCK Kommanditgesellschaft auf Aktien MER.SW	0	-	DE
Merck KGaA MRK.DE	0	-	DE
Takeda Pharmaceutical Company Limited 4502.T	0	-	JP
Galderma Group AG GALD.SW	0	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	5	x119	IN

Unternehmen

Anzahl der Aktiensplits

Kumulierter Multiplikator

Land